Round 1: Immunotherapy vs Alternative Therapy
04/24/2025
The debate opens with an insightful review of existing treatment paradigms for metastatic NSCLC. In patient scenarios where pre-existing conditions previously hindered immunotherapy use, panelists discuss which treatment should be used as second-line therapy.
To hear arguments related to adding radiation therapy or switching treatments, see Round 2.
To hear arguments related to for TTFields vs against TTFields, see Round 3.
Transcript coming soon!
This is a non-CME activity. The views and opinions expressed by the presenter(s) do not necessarily reflect the views and opinions of the Oncology Learning Network, HMP Global, or its employees and affiliates.
Moderator: Corey Langer, MD
Director of Thoracic Oncology
Abramson Cancer Center
Hospital of the University of Pennsylvania
For Immunotherapy: Jamie E Chaft, MD
Thoracic Medical Oncologist
Memorial Sloan Kettering Cancer Center
For Alternative Therapy: Edward Garon, MD
Thoracic Medical Oncologist
University of California
